ClinicalTrials.gov registry snapshot / 2026-07-24

Peptide trials,
without the maze.

Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.

268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program

Study status is not drug rank.

Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.

Official registry finder

Filter the exact records.

Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.

Reset
10matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
Program and recordStatusPhase and enrollmentLocationsPrimary completionRegistry updateSource
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011 / Novo Nordisk A/SRecruitingVerified 2025-05Phase 1177 estimated2 recruiting2 listed / 1 countriesMar 26, 2026estimatedMay 25, 2025ClinicalTrials.govOpen NCT06719011
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 / RAMBO / Novo Nordisk A/SRecruitingVerified 2025-07Phase 1144 estimated1 recruiting1 listed / 1 countriesMay 3, 2028estimatedJul 25, 2025ClinicalTrials.govOpen NCT07010432
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 / Novo Nordisk A/SRecruitingVerified 2025-10Phase 180 estimated2 recruiting2 listed / 1 countriesOct 12, 2027estimatedOct 8, 2025ClinicalTrials.govOpen NCT07184086
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3460 estimated16 recruiting120 listed / 26 countriesMar 20, 2030estimatedJul 17, 2026ClinicalTrials.govOpen NCT07253285
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 / Novo Nordisk A/SRecruitingVerified 2026-04Phase 1100 estimated1 recruiting1 listed / 1 countriesJan 26, 2027estimatedApr 13, 2026ClinicalTrials.govOpen NCT07411560
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 / RASMUS / Novo Nordisk A/SRecruitingVerified 2026-05Phase 1100 estimated1 recruiting1 listed / 1 countriesApr 28, 2028estimatedMay 7, 2026ClinicalTrials.govOpen NCT07527195
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953 / Novo Nordisk A/SRecruitingVerified 2026-05Phase 1120 estimated1 recruiting1 listed / 1 countriesApr 13, 2027estimatedMay 15, 2026ClinicalTrials.govOpen NCT07557953
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 32,500 estimated135 recruiting303 listed / 19 countriesFeb 23, 2028estimatedJul 8, 2026ClinicalTrials.govOpen NCT07564414
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 / Novo Nordisk A/SRecruitingVerified 2026-06Phase 1234 estimated1 recruiting1 listed / 1 countriesMay 28, 2027estimatedJun 26, 2026ClinicalTrials.govOpen NCT07597018
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 / Novo Nordisk A/SRecruitingVerified 2026-06Phase 1114 estimated10 recruiting11 listed / 1 countriesNov 19, 2027estimatedJun 25, 2026ClinicalTrials.govOpen NCT07607587
Clinical trial finder FAQ

Status, location, and enrollment are different fields.

These answers prevent the most common registry-search errors before a reader follows an official source.

01

Are any Retatrutide clinical trials recruiting?

Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.

02

How do I find a peptide clinical trial near me?

Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.

03

Does Recruiting mean I can join the trial?

No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.

04

Are the drugs in this clinical trial finder FDA approved?

A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.

05

Why do only some registry records show posted results?

11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.

06

How current is the peptide clinical trial data?

The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.

Evidence boundary

A registry finder, not an enrollment service.

A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.

Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.

Read the official API documentation ↗Understand evidence categories →